Humanigen (HGEN) Stock

An indictment unsealed on Monday charged the former chief scientific officer of biopharmaceutical company Humanigen with engaging in an insider trading scheme involving the firm's stock, the U.S. Justice Department said.

Humanigen (OTCMKTS: HGEN ) stock is falling hard on Friday after the company filed for Chapter 11 bankruptcy protection. This bankruptcy filing comes after Humanigen failed to secure regulatory approval for its Covid-19 treatment lenzilumab.

Drug developer Humanigen HGEN.PK has filed for voluntary Chapter 11 bankruptcy, according to a court filing, after struggling to get regulatory approval for its COVID-19 treatment.

Humanigen Inc shares have plummeted more than 90% over the past month, and now trades at a little over a penny per share, after the clinical-stage biopharmaceutical company said it is facing bankruptcy after negotiations for a reverse merger with an unnamed, privately-held biopharma company ended.   Humanigen noted that it is unable to find another source of financing that would allow it to maintain its Nasdaq listing, including a minimum share price of $1, and it is now trading on OTC Pink Market.

Humanigen (NASDAQ: HGEN ) stock is falling hard on Tuesday after the company warned investors it can't keep listing requirements. According to a filing from the company, it is no longer compliant with Nasdaq listing standards.

Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.